Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin

Sicras Mainar, AntoniRejas, JavierPérez-Paramo, MariaSánchez-Álvarez, LuisNavarro-Artieda, RuthDarbà, Josep2019-05-242020-02-282019-021473-7167https://hdl.handle.net/2445/133837Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...)13 p.application/pdfeng(c) Informa Healthcare, 2019MedicamentsMedicaments genèricsAnàlisi cost-beneficiNeuropsicofarmacologiaTractament del dolorAnsietatDrugsGeneric drugsCost effectivenessNeuropsychopharmacologyPain treatmentAnxietyConsequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalininfo:eu-repo/semantics/article6860102019-05-24info:eu-repo/semantics/openAccess